Hoth Therapeutics (NASDAQ:HOTH) announced Thursday that it has received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I of its HT-001 clinical program.
Beam Therapeutics (NASDAQ:BEAM) bolstered its position as a leader in the genetic medicine space on Thursday, reporting a formidable cash pile of $1.1 billion as of September 30, 2025.
Boston Scientific Corp. (NYSE:BSX) announced a definitive agreement on Thursday to acquire Penumbra (NYSE:PEN) in a cash-and-stock transaction valuing the company at $374 per share, or an enterprise value of approximately $14.5 billion.
Aurora Cannabis (NASDAQ:ACB) has entered the final stage of production trials for a new generation of cannabis cultivars designed to be naturally immune to powdery mildew, a breakthrough that could eliminate one of the industry's most expensive cultivation risks.
Intuitive Surgical (NASDAQ:ISRG) hit a major financial landmark Wednesday, reporting preliminary 2025 revenue of $10.06 billion, a 21% increase over the prior year.
The results, fueled by the rapid rollout of the next-generation da Vinci 5 system, underscore the company’s dominant grip on the robotic-assisted surgery market as it transitions from a niche technology provider to a foundational healthcare infrastructure giant.
ImmunityBio (NASDAQ:IBRX) announced Wednesday that the Saudi Food and Drug Authority (SFDA) has approved ANKTIVA® (nogapendekin alfa inbakicept) for the treatment of non-muscle invasive bladder cancer (NMIBC).
Dr. Reddy’s Laboratories (NYSE:RDY) announced Wednesday the first-to-market launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution, 0.7%, providing a lower-cost generic equivalent to Alcon’s Extra Strength Pataday® Once-Daily Relief.
Emergent BioSolutions (NYSE:EBS) received FDA approval Wednesday for a redesigned, compact carrying case for its over-the-counter (OTC) NARCAN® Nasal Spray, a move aimed at overcoming the "stigma of carrying" that has long hampered community-level overdose responses.
NRx Pharmaceuticals (NASDAQ:NRXP) achieved a pivotal regulatory milestone Wednesday, announcing the submission of a massive real-world dataset to the U.S. Food and Drug Administration (FDA) to support the accelerated approval of NRX-100, its proprietary preservative-free ketamine.
HUTCHMED (China) (NASDAQ:HCM) and partner AstraZeneca (NYSE:AZN) reached a major scientific milestone Wednesday with the publication of full Phase III SACHI trial results in The Lancet.
SEALSQ Corp (NASDAQ:LAES), the semiconductor and post-quantum cryptography subsidiary of WISeKey (NASDAQ:WKEY), announced Wednesday it has entered a non-binding Memorandum of Understanding (MOU) to potentially acquire a majority stake in QUOBLY, a Grenoble-based pioneer in silicon-based quantum computing.
AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.
